Elutia sells SimpliDerm business to Cellution Biologics for up to $11 million

Elutia Inc. has completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million. The transaction includes an initial $8 million cash payment, subject to adjustments, and up to $3 million in contingent milestone payments over 18 months. This divestiture allows Elutia to redirect resources toward its NXT-41x program, with FDA clearance targeted for early 2027 and commercial launch planned for 2028.

Elutia closed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to USD 11 million. * Received USD 8 million in cash at closing, subject to customary inventory adjustments and transaction expenses. * Deal includes up to USD 3 million of contingent milestone payments over the next 18 months. * Divestiture shifts resources toward NXT-41x, with FDA clearance targeted for the first half of 2027. * Proceeds support funding through the first full year of the planned NXT-41x commercial launch in 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099731), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

ELUT